Elinzanetant in postmenopausal women with sleep disturbance: results from the randomized, phase II NIRVANA study
Clicks: 6
ID: 322836
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
1.5
/100
6 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #41 of 189 articles by views in Sleep & breathing = Schlaf & Atmung
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 189 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
STUDY OBJECTIVES: Menopausal sleep disturbances can negatively impact quality of life. Elinzanetant, a dual neurokinin (NK)-1/NK-3 receptor antagonist, reduced self-reported sleep disturbance in postmenopausal women with moderate-to-severe vasomotor symptoms (VMS) in Phase III OASIS trials. NIRVANA explored elinzanetant's effect on multimodal measures of objective and subjective sleep disturbance in postmenopausal women. MATERIALS AND METHODS: Postmenopausal women (N = 110; 40-65 years) with moderate-to-severe VMS (≥20/week) and sleep disturbance (polysomnography [PSG] wakefulness after sleep onset [WASO] ≥30 min) were randomized 1:1 to receive elinzanetant 120 mg or placebo for 12 weeks. Sleep disturbance was assessed using PSG; daily Sleep Diary; and nightly contactless home-monitoring (Sleepiz One+ subgroup). The effect of elinzanetant versus placebo was analyzed using mixed-model repeated measures. RESULTS: Elinzanetant was estimated to reduce PSG WASO at Week 4 versus placebo (least square [LS]-mean difference = -22.50 minutes, 90% CI: -35.47, -9.52). Minimal group differences between treatment arms were estimated at Week 12 for PSG WASO (LS-mean difference = -0.94 minutes, 90% CI: -13.96, 12.09). When including all available PSG data across the 12-week period, post hoc random coefficient modeling indicated treatment effects favoring elinzanetant for WASO, total sleep time, sleep efficiency, latency to persistent sleep, number of awakenings, arousal index, and % Stage N2 sleep. Treatment effects on WASO and awakenings favoring elinzanetant were observed with Sleepiz One+ and Sleep Diary across 12 weeks. CONCLUSION: In this sleep-focused study, elinzanetant reduced WASO at Week 4 and led to estimated improvements in sleep continuity over 12 weeks, supported by multimodal subjective and objective sleep outcomes. CLINICAL TRIAL: A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause (NIRVANA), https://clinicaltrials.gov/study/NCT06112756, NCT06112756, date of registration 2023-11-01.
| Reference Key |
openalex_W7171536291
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Fiona C. Baker, Hadine Joffe, Claudio N Soares, Pauline M. Maki, Malek Bajbouj, Rossella E Nappi, Gary Zammit, Cecilia Caetano, Ulrike Krahn, Huda Shalhoub, Frank Krämer, Hoi-Shen Radcliffe, Christian Seitz |
| Journal | Sleep & breathing = Schlaf & Atmung |
| Year | 2026 |
| DOI |
10.1093/sleep/zsag208
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.